Radioligand therapy gains momentum as experts discuss expanding patient impact
In a recent episode of the Denatured podcast presented by Curium, host Jennifer Smith-Parker spoke with Mike Patterson, CEO North America, and Sabine Brookman-May, Vice President and Head of Global Clinical Development, about radioligand therapy.
The guests described how radioligand therapy merges diagnostic imaging with targeted treatment, creating a platform that could benefit more than 14 million patients worldwide.
They also highlighted Curium’s plans to expand manufacturing capacity in the United States and accelerate the rollout of these therapies, aiming to improve outcomes for cancer patients.
The discussion underscored the potential for continued clinical development and scaling to reshape cancer care in the years ahead.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “How radioligand therapy is rewriting cancer care”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that